[Iodinated and gadolinium-based contrast agents and kidney disease: consensus statement of the Austrian Society for Radiology (OERG) and the Austrian Society of Nephrology (ÖGN)].

Authors

Gertraud Heinz, Martin Windpessl, Alexandra Ökrösi, Christian Krestan, Katharina Lampichler, Gregor Bond, Marcus Säemann, Katharina Hohenstein-Scheibenecker

Published in

Wiener klinische Wochenschrift. Oct 27, 2026. Epub Oct 27, 2026.

Abstract

Iodinated and gadolinium-based contrast agents are indispensable in radiological diagnostics; however, they were previously considered problematic in patients with chronic kidney disease (CKD) due to potential side effects. Study data from the past 15 years have led to the realization that the nephrotoxic potential of contrast agents has been overstated and that a reassessment is warranted. This consensus paper aims to standardize the intravascular use of contrast agents in the CKD population in a practical manner, based on scientific evidence and international guidelines, enabling both optimal diagnostic yield and maximum patient safety.
The Austrian Radiological Society (OERG) and the Austrian Society of Nephrology each nominated four experts in a working group to draft consensus guidelines regarding the safe use of contrast agents in patients with impaired kidney function. Following an initial meeting of this working group a literature search was conducted in various medical databases (PubMed, Embase, Cochrane Central Register of Controlled Trials) and pertinent guidelines of various international specialist societies were identified. The scientific work and guidelines were evaluated in five further meetings of the working group. The recommendations for the safe use of contrast agents were compiled in a consensus.
The recommendations could be summarized in 11 consensus statements. In addition, an algorithm for the administration of iodinated contrast agents in patients with impaired kidney function was created.
This consensus paper, endorsed by the OERG and ÖGN provides a standardized approach for the intravascular administration of contrast agents in individuals with CKD. Emphasis is placed on the diagnostic benefits of a contrast agent-assisted investigation in comparison to the potential risk of an associated kidney damage.

PMID:
42944772
Bibliographic data and abstract were imported from PubMed on 28 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.